SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Felix B who wrote (2815)12/11/2019 11:51:31 PM
From: Miljenko Zuanic  Respond to of 3557
 
It is new, conduced by Sanofi (International, US included).
primary:
Rate of moderate-to-severe acute Exacerbations in chronic obstructive pulmonary disease (AECOPD) patients [ Time Frame: Over up to 52 weeks treatment period ]
Annualized rate of moderate-to-severe AECOPD over up to 52 weeks.

clinicaltrials.gov

Sanofi did not yet decided to kill COPD indication (can not do without REGN), AD indication still ongoing. Asthma probably dead.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News